Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Fulcrum Therapeutics, Inc. (FULC) since 2019 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Fulcrum Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1680581.
Total stock buying since 2019: $9,501,676.
Total stock sales since 2019: $7,544,121.
Total stock option exercises since 2019: $3,444,471.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 498 | $2,519 | 0 | $0 |
| 2024 | 0 | $0 | 5,120 | $59,051 | 150,000 | $490,500 |
| 2023 | 0 | $0 | 6,976 | $102,185 | 0 | $0 |
| 2022 | 0 | $0 | 237,939 | $3,522,611 | 237,939 | $1,865,437 |
| 2021 | 11,100 | $101,676 | 151,607 | $2,657,832 | 116,785 | $915,594 |
| 2020 | 0 | $0 | 63,209 | $1,199,923 | 24,202 | $172,940 |
| 2019 | 596,250 | $9,400,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-05 | 0 | $0 | 498 | $2,519 | 0 | $0 |
| 2024-07 | 0 | $0 | 0 | $0 | 150,000 | $490,500 |
| 2024-05 | 0 | $0 | 236 | $1,831 | 0 | $0 |
| 2024-03 | 0 | $0 | 4,884 | $57,220 | 0 | $0 |
| 2023-05 | 0 | $0 | 210 | $695 | 0 | $0 |
| 2023-01 | 0 | $0 | 6,766 | $101,490 | 0 | $0 |
| 2022-06 | 0 | $0 | 138,057 | $1,110,713 | 138,057 | $1,082,364 |
| 2022-04 | 0 | $0 | 99,882 | $2,411,898 | 99,882 | $783,073 |
| 2021-08 | 0 | $0 | 111,785 | $2,131,237 | 111,785 | $876,394 |
| 2021-06 | 11,100 | $101,676 | 0 | $0 | 0 | $0 |
| 2021-03 | 0 | $0 | 10,000 | $121,580 | 0 | $0 |
| 2021-02 | 0 | $0 | 13,215 | $191,687 | 5,000 | $39,200 |
| 2021-01 | 0 | $0 | 16,607 | $213,328 | 0 | $0 |
| 2020-09 | 0 | $0 | 0 | $0 | 6,350 | $49,784 |
| 2020-07 | 0 | $0 | 6,522 | $128,619 | 2,951 | $23,135 |
| 2020-06 | 0 | $0 | 14,752 | $301,742 | 3,061 | $15,205 |
| 2020-05 | 0 | $0 | 19,061 | $347,629 | 5,752 | $37,087 |
| 2020-03 | 0 | $0 | 2,143 | $37,911 | 0 | $0 |
| 2020-02 | 0 | $0 | 15,731 | $295,952 | 6,088 | $47,729 |
| 2020-01 | 0 | $0 | 5,000 | $88,070 | 0 | $0 |
| 2019-07 | 596,250 | $9,400,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-08 | Tourangeau Greg (Principal Accounting Officer) | Sale | 498 | 5.06 | 2,519 |
| 2024-07-03 | Sapir Alex (See Remarks) | Option Ex | 150,000 | 3.27 | 490,500 |
| 2024-05-07 | Tourangeau Greg (Principal Accounting Officer) | Sale | 236 | 7.76 | 1,831 |
| 2024-03-08 | Tourangeau Greg (Vice President, Finance) | Sale | 4,884 | 11.72 | 57,220 |
| 2023-05-10 | Tourangeau Greg (Principal Accounting Officer) | Sale | 210 | 3.31 | 695 |
| 2023-01-13 | Gould Robert J (Interim President & CEO) | Sale | 6,766 | 15.00 | 101,490 |
| 2022-06-07 | Gould Robert J (Director) | Sale | 71,435 | 8.09 | 577,909 |
| 2022-06-07 | Gould Robert J (Director) | Option Ex | 71,435 | 7.84 | 560,050 |
| 2022-06-06 | Gould Robert J (Director) | Sale | 24,382 | 8.10 | 197,591 |
| 2022-06-06 | Gould Robert J (Director) | Option Ex | 24,382 | 7.84 | 191,154 |
| 2022-06-03 | Gould Robert J (Director) | Sale | 25,551 | 7.95 | 203,053 |
| 2022-06-03 | Gould Robert J (Director) | Option Ex | 25,551 | 7.84 | 200,319 |
| 2022-06-02 | Gould Robert J (Director) | Sale | 16,689 | 7.92 | 132,160 |
| 2022-06-02 | Gould Robert J (Director) | Option Ex | 16,689 | 7.84 | 130,841 |
| 2022-04-07 | Gould Robert J (Director) | Sale | 5,631 | 24.02 | 135,228 |
| 2022-04-07 | Gould Robert J (Director) | Option Ex | 5,631 | 7.84 | 44,147 |
| 2022-04-05 | Gould Robert J (Director) | Sale | 52,552 | 24.26 | 1,274,753 |
| 2022-04-05 | Gould Robert J (Director) | Option Ex | 52,552 | 7.84 | 412,007 |
| 2022-04-04 | Gould Robert J (Director) | Sale | 7,235 | 24.02 | 173,748 |
| 2022-04-04 | Gould Robert J (Director) | Option Ex | 7,235 | 7.84 | 56,722 |
| 2022-04-01 | Gould Robert J (Director) | Sale | 34,464 | 24.03 | 828,169 |
| 2022-04-01 | Gould Robert J (Director) | Option Ex | 34,464 | 7.84 | 270,197 |
| 2021-08-11 | Stuart Bryan (See Remarks) | Sale | 28,000 | 23.75 | 665,000 |
| 2021-08-11 | Stuart Bryan (See Remarks) | Option Ex | 28,000 | 7.84 | 219,520 |
| 2021-08-10 | Moxham Christopher (Chief Scientific Officer) | Sale | 51,785 | 17.50 | 906,237 |
| 2021-08-10 | Moxham Christopher (Chief Scientific Officer) | Option Ex | 51,785 | 7.84 | 405,994 |
| 2021-08-10 | Stuart Bryan (See Remarks) | Sale | 32,000 | 17.50 | 560,000 |
| 2021-08-10 | Stuart Bryan (See Remarks) | Option Ex | 32,000 | 7.84 | 250,880 |
| 2021-06-28 | Morabito Christopher (Chief Medical Officer) | Buy | 1,100 | 9.16 | 10,076 |
| 2021-06-28 | Geraghty James A (Director) | Buy | 10,000 | 9.16 | 91,600 |
| 2021-03-16 | Gould Robert J (See Remarks) | Sale | 789 | 12.43 | 9,805 |
| 2021-03-15 | Gould Robert J (See Remarks) | Sale | 9,211 | 12.13 | 111,775 |
| 2021-02-22 | Thomson Peter G. (VP Finance & Accounting) | Sale | 5,000 | 14.72 | 73,580 |
| 2021-02-22 | Thomson Peter G. (VP Finance & Accounting) | Option Ex | 5,000 | 7.84 | 39,200 |
| 2021-02-16 | Gould Robert J (See Remarks) | Sale | 8,215 | 14.38 | 118,107 |
| 2021-01-21 | Thomson Peter G. (VP Finance & Accounting) | Sale | 6,607 | 14.00 | 92,498 |
| 2021-01-20 | Gould Robert J (See Remarks) | Sale | 10,000 | 12.08 | 120,830 |
| 2020-09-14 | Wallace Owen B. (Chief Scientific Officer) | Option Ex | 6,350 | 7.84 | 49,784 |
| 2020-07-08 | Wallace Owen B. (Chief Scientific Officer) | Sale | 2,951 | 20.00 | 59,020 |
| 2020-07-08 | Wallace Owen B. (Chief Scientific Officer) | Option Ex | 2,951 | 7.84 | 23,135 |
| 2020-07-08 | Gould Robert J (See Remarks) | Sale | 2,500 | 20.00 | 50,000 |
| 2020-07-01 | Cadavid Diego (SVP Clinical Development) | Sale | 1,071 | 18.30 | 19,599 |
| 2020-06-30 | Wallace Owen B. (Chief Scientific Officer) | Sale | 141 | 20.00 | 2,820 |
| 2020-06-30 | Wallace Owen B. (Chief Scientific Officer) | Option Ex | 141 | 7.84 | 1,105 |
| 2020-06-25 | Cadavid Diego (SVP Clinical Development) | Sale | 1,459 | 22.00 | 32,098 |
| 2020-06-25 | Cadavid Diego (SVP Clinical Development) | Option Ex | 1,459 | 4.83 | 7,046 |
| 2020-06-25 | Gould Robert J (See Remarks) | Sale | 2,500 | 20.80 | 51,992 |
| 2020-06-10 | Cadavid Diego (SVP Clinical Development) | Sale | 401 | 22.00 | 8,822 |
| 2020-06-10 | Cadavid Diego (SVP Clinical Development) | Option Ex | 401 | 4.83 | 1,936 |
| 2020-06-09 | Gould Robert J (See Remarks) | Sale | 156 | 20.00 | 3,120 |
| 2020-06-05 | Cadavid Diego (SVP Clinical Development) | Sale | 451 | 20.18 | 9,100 |
| 2020-06-05 | Cadavid Diego (SVP Clinical Development) | Option Ex | 451 | 4.83 | 2,178 |
| 2020-06-05 | Gould Robert J (See Remarks) | Sale | 3,433 | 20.17 | 69,250 |
| 2020-06-04 | Cadavid Diego (SVP Clinical Development) | Sale | 226 | 20.05 | 4,531 |
| 2020-06-04 | Cadavid Diego (SVP Clinical Development) | Option Ex | 226 | 4.83 | 1,091 |
| 2020-06-04 | Gould Robert J (See Remarks) | Sale | 1,300 | 20.05 | 26,058 |
| 2020-06-03 | Cadavid Diego (SVP Clinical Development) | Sale | 338 | 20.18 | 6,819 |
| 2020-06-03 | Cadavid Diego (SVP Clinical Development) | Option Ex | 338 | 4.83 | 1,632 |
| 2020-06-03 | Gould Robert J (See Remarks) | Sale | 1,500 | 20.13 | 30,192 |
| 2020-06-02 | Cadavid Diego (SVP Clinical Development) | Sale | 45 | 20.00 | 900 |
| 2020-06-02 | Cadavid Diego (SVP Clinical Development) | Option Ex | 45 | 4.83 | 217 |
| 2020-06-02 | Gould Robert J (See Remarks) | Sale | 2,797 | 20.00 | 55,940 |
| 2020-06-01 | Gould Robert J (See Remarks) | Sale | 5 | 20.00 | 100 |
| 2020-05-29 | Cadavid Diego (SVP Clinical Development) | Sale | 200 | 20.04 | 4,007 |
| 2020-05-29 | Cadavid Diego (SVP Clinical Development) | Option Ex | 200 | 4.83 | 966 |
| 2020-05-29 | Gould Robert J (See Remarks) | Sale | 1,390 | 20.08 | 27,911 |
| 2020-05-28 | Wallace Owen B. (Chief Scientific Officer) | Sale | 2,232 | 20.00 | 44,640 |
| 2020-05-28 | Wallace Owen B. (Chief Scientific Officer) | Option Ex | 2,232 | 7.84 | 17,498 |
| 2020-05-28 | Cadavid Diego (SVP Clinical Development) | Sale | 600 | 20.00 | 12,000 |
| 2020-05-28 | Cadavid Diego (SVP Clinical Development) | Option Ex | 600 | 4.83 | 2,898 |
| 2020-05-28 | Gould Robert J (See Remarks) | Sale | 1,919 | 20.01 | 38,391 |
| 2020-05-27 | Wallace Owen B. (Chief Scientific Officer) | Sale | 448 | 20.00 | 8,960 |
| 2020-05-27 | Wallace Owen B. (Chief Scientific Officer) | Option Ex | 448 | 7.84 | 3,512 |
| 2020-05-26 | Wallace Owen B. (Chief Scientific Officer) | Sale | 412 | 20.00 | 8,240 |
| 2020-05-26 | Wallace Owen B. (Chief Scientific Officer) | Option Ex | 412 | 7.84 | 3,230 |
| 2020-05-26 | Gould Robert J (See Remarks) | Sale | 2,500 | 20.00 | 50,000 |
| 2020-05-12 | Cadavid Diego (SVP Clinical Development) | Sale | 1,860 | 18.00 | 33,480 |
| 2020-05-12 | Cadavid Diego (SVP Clinical Development) | Option Ex | 1,860 | 4.83 | 8,983 |
| 2020-05-11 | Thomson Peter G. (VP Finance & Accounting) | Sale | 7,500 | 16.00 | 120,000 |
| 2020-03-02 | Cadavid Diego (SVP Clinical Development) | Sale | 2,143 | 17.69 | 37,911 |
| 2020-02-24 | Thomson Peter G. (VP Finance & Accounting) | Sale | 5,000 | 17.41 | 87,050 |
| 2020-02-19 | Wallace Owen B. (Chief Scientific Officer) | Sale | 6,088 | 20.00 | 121,760 |
| 2020-02-19 | Wallace Owen B. (Chief Scientific Officer) | Option Ex | 6,088 | 7.84 | 47,729 |
| 2020-02-19 | Gould Robert J (See Remarks) | Sale | 2,500 | 20.00 | 50,000 |
| 2020-02-03 | Cadavid Diego (SVP Clinical Development) | Sale | 2,143 | 17.33 | 37,142 |
| 2020-01-23 | Thomson Peter G. (VP Finance & Accounting) | Sale | 5,000 | 17.61 | 88,070 |
| 2019-07-22 | 6 Dimensions Capital, L.p. (10% Owner) | Buy | 118,750 | 16.00 | 1,900,000 |
| 2019-07-22 | Trv Gp Iv, Llc (10% Owner) | Buy | 81,250 | 16.00 | 1,300,000 |
| 2019-07-22 | Casdin Eli (10% Owner) | Buy | 140,000 | 15.00 | 2,100,000 |
| 2019-07-22 | Tepper Robert I (10% Owner) | Buy | 81,250 | 16.00 | 1,300,000 |
| 2019-07-22 | Levin Mark J (Director) | Buy | 81,250 | 16.00 | 1,300,000 |
| 2019-07-22 | Sanofi (10% Owner) | Buy | 93,750 | 16.00 | 1,500,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of FULC listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Fulcrum Therapeutics, Inc. (symbol FULC, CIK number 1680581) see the Securities and Exchange Commission (SEC) website.